Prevalence, Types and Treatment of Tuberculosis: A Review


Saema Salim


Tuberculosis (TB) has reemerged as one of the main cause of death in human beings in recent years. TB is caused by a group of species called Mycobacterium tuberculosis complex, and it causes three million deaths each year around the world. In 2010, the global estimated incidence of TB was about 8.0 million. The number of deaths from TB among HIV-negative patients was 1.0 million while the number of deaths among the HIV-positive TB was about 0.40 million. The higher incident and elevation of MDR cases demand efforts to shift focus to various control strategies against TB. According to WHO, in 2014 magnitude of TB was recorded as 126 positive cases per 0.1 million population in the world. Pakistan ranks fourth in high TB burden countries where each year approximately 297,000 TB cases are reported. Tuberculosis can be comprehensively grouped into two main types; pulmonary and extra pulmonary tuberculosis. Pulmonary tuberculosis affects the lungs and is most common type of TB. In 15 to 20 % cases of the active TB, the infection spreads from lungs to different parts of the body. This condition is called extra-pulmonary tuberculosis. Different treatment regimens are available for tuberculosis.




How to Cite
Salim S. Prevalence, Types and Treatment of Tuberculosis: A Review. Sci Inquiry Rev. [Internet]. 2020Dec.31 [cited 2021Apr.21];4(4):41-8. Available from:


1. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Sci. 2002 Mar 15;295(5562):2042-6.
2. Beresford B, Sadoff JC. Update on research and development pipeline: tuberculosis vaccines. Clinical Infectious Diseases. 2010 May 15;50(Supplement_3):S178-83.
3. World Health Organization. Global tuberculosis control: WHO report 2011. InGlobal tuberculosis control: WHO report 2011 2011.
4. World Health Organization. Global tuberculosis report 2013. World Health Organization; 2013.
5. World Health Organization Global tuberculosis Report. Avenue Appia, 1211, 2014, Geneva27, Switzerland.
6. Lee KW, Lee JM, Jung KS. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J Korean Med Sci., 2001, 16(5):537-43.
7. World Health Organization. Global tuberculosis control: WHO report 2011. InGlobal tuberculosis control: WHO report 2011 2011.
8. Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120(4):316-353.
9. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician. 2005;72(9):1761-1768.
10. Doetsch RN. Benjamin Marten and his" New Theory of Consumptions". Microbiological reviews. 1978 Sep;42(3):521.
11. Daniel TM. Robert Koch and the pathogenesis of tuberculosis [Founders of Our Knowledge]. Int J Tuber Lung Dis. 2005 Nov 1;9(11):1181-2.
12. Daniel TM, Bates JH, Downes KA. History of tuberculosis. Tuberculosis: Pathogenesis, Protection, and Control. 1994 May 16:13-24.
13. Schlossberg DL. Tuberculosis and nontuberculous mycobacterial infections. John Wiley & Sons; 2020 Jul 10.
14. Dannenberg Jr AM. Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit Model. ASM Press; 2006.
15. David HL, Jahan MT, Jumin A, et al. Numerical taxonomy analysis of Mycobacterium africanum. Int J Syst Evol Microbiol. 1978 Oct 1;28(4):464-72.
16. Niemann S, Richter E, Rüsch-Gerdes S. Differentiation among Members of the Mycobacterium tuberculosis Complex by Molecular and Biochemical Features: Evidence for Two Pyrazinamide-Susceptible Subtypes of M. bovis. J clin microbiol. 2000 Jan 1;38(1):152-7.
17. Rivero A, Márquez M, Santos J, et al. High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B. Clin Infect Dis. 2001 Jan 1;32(1):159-61.
18. Van Soolingen D, Hoogenboezem T, De Haas PE, et al. A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int J Syst Evolut Microbiol. 1997 Oct 1;47(4):1236-45.
19. Delogu G, Fadda G. The quest for a new vaccine against tuberculosis. J of Infect in Developing Countries. 2009;3(1):5-15.
20. Krauss H, Schiefer HG, Weber A. Infectious Diseases Transmissible from Animals to Humans, 3rd ed. 2003;Washington D.C. USA.
21. Science Photo Library.
22. Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proceed Nation Acad Sci. 2002 Mar 19;99(6):3684-9.

23. Frieden TR, Sterling TR, Munsiff SS. et al. Tuberculosis. Lancet. 2003;362:887-99.

24. Brennan PJ. Structure of mycobacteria: recent developments in defining cell wall carbohydrates and proteins. Rev Infect Dis. 1989 Mar 1;11(Supplement_2):S420-30.
25. Segal W. Growth Dynamics of in Vivo and in Vitro Grown Mycobacterial Pathogens. The Mycobacteria. A Sourcebook. Marcel Dekker, Inc., New York, NY. 1984:547-73.
26. Hybiske K, Stephens RS. Exit strategies of intracellular pathogens. Nat Rev Microbiol. 2008 Feb;6(2):99-110.
27. Meena LS. Survival mechanisms of pathogenic Mycobacterium tuberculosis H37Rv. FEBS J. 2010 Jun 1;277(11):2416-27.
28. Behr MA, Sherman DR. Mycobacterial virulence and specialized secretion: same story, different ending. Nat Med. 2007 Mar;13(3):286-7.
29. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis. 2011 Nov 1;91(6):497-509.
30. Sakula A. Robert Koch: centenary of the discovery of the tubercle bacillus, 1882. Thorax. 1982 Apr 1;37(4):246-51.
31. Chadwick MV. Mycobacteria. 1982, Wright PSG, London, USA.
32. Petti CA, Weinstein MP, Carroll KC. Systems for Detection and Identification of Bacteria and Yeasts. Manual of Clinical Microbiology, 10th ed. 2011 Jan 1:15-26.
33. Ouellet H, Johnston JB, de Montellano PR. Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis. Trends Microbiol. 2011 Nov 1;19(11):530-9.
34. Rutala WA. APIC guideline for selection and use of disinfectants. Am J Infect Control. 1990 Apr 1;18(2):99-117.
35. Dorhoi A, Reece ST, Kaufmann SH. For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunological Rev. 2011 Mar;240(1):235-51.
36. Glickman MS, Jacobs WR. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell. 2001 Feb 23;104(4):477-85.
37. Chan J, Fan XD, Hunter SW, et al. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infection Immunity. 1991 May 1;59(5):1755-61.
38. Schlesinger LS, Kaufman TM, Iyer S, et al. Differences in mannose receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by human macrophages. J Immunol. 1996 Nov 15;157(10):4568-75.
39. Stear MJ. OIE manual of diagnostic tests and vaccines for terrestrial animals. Parasitol. 2005 Jun;130(6):727-.
40. Sreevatsan S, Pan XI, Stockbauer KE, et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proceed Nat Acad Sci. 1997 Sep 2;94(18):9869-74.
41. Fleischmann RD, Alland D, Eisen JA, et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct 1;184(19):5479-90.
42. Baril L, Caumes E, Truffot-Pernot C, et al. Tuberculosis caused by Mycobacterium africanum associated with involvement of the upper and lower respiratory tract, skin, and mucosa. Clin Infect Dis. 1995 Sep 1;21(3):653-5.
43. Meyer CG, Scarisbrick G, Niemann S, et al. Pulmonary tuberculosis: virulence of Mycobacterium africanum and relevance in HIV co-infection. Tuberculosis. 2008 Sep 1;88(5):482-9.
44. David HL, Jahan MT, Jumin A, et al. Numerical taxonomy analysis of Mycobacterium africanum. Int J Syst Evolut Microbiol. 1978 Oct 1;28(4):464-72.
45. De Jong BC, Antonio M, Gagneux S. Mycobacterium africanum—review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis. 2010 Sep 28;4(9):e744.
46. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nat. 2001 Feb;409(6823):1007-11.
47. Browne SG. Some aspects of the history of leprosy: the leprosie of yesterday. Proc R Soc Med. 1975;68(8):485-493.
48. Sansonetti P, Lagrange PH. The immunology of leprosy: speculations on the leprosy spectrum. Rev Infect Dis. 1981;3(3):422-69.
49. Martinez TS, Figueira MM, Cost AV,et al. Oral mucosa as a source of Mycobacterium leprae infection and transmission, and implications of bacterial DNA detection and the immunological status. Clin Microbiol and Infect. 2011;17(11):1653-1658.
50. Beyene D, Aseffa A, Harboe M, et al. Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia. Epidemiol Infect. 2003 Oct;131(2):841-8.
51. Desikan KV, Sreevatsa. Extended studies on the viability of Mycobacterium leprae outside the human body. Leprosy Rev. 1995;66(4):287-295.
52. Van Beers SM, de Wit MY, Klatser PR. The epidemiology of Mycobacterium leprae: recent insight. FEMS Microbiol Lett. 1996 Mar 1;136(3):221-30.
53. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis. 2006;10(8):829-837.
54. Eker B, Ortmann J, Migliori GB, et al. Multidrug-and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis. 2008 Nov;14(11):1700.
55. Wehrli W, Knüsel F, Schmid K, et al. Interaction of rifamycin with bacterial RNA polymerase. Proceedings of the National Academy of Sciences of the United States of America. 1968 Oct;61(2):667.
56. Dooley SW, Jarvis WR, Martine WJ, et al. MDR Tuberculosis (editorial). Ann Intern Med, 1992;117(3):257-258.
57. Edlin BR, Tokers JI, Greeko MH, et al. An outbreak of multidrug resistant tuberculosis among hospitalized patients with the Acquired Immuno-Deficiency syndrome. N Engl J Med. 1992;326(23):1514-1521.
58. Pearson ML, Jareb JA, Freiden TR. Nosocomial transmission of multidrug resistant tuberculosis-a risk to patients and health care workers. Ann Intern Med. 1992;117(3):191-196.
59. Faustini A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax;2006:61(2), 158-163.
60. Telenti A. Genetics of drug resistant Tuberculosis. Thorax. 1998;53(9):793-797.
61. Miller MA, Thibert L, Desjardins F, et al. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J Clin Microbiol. 1995;33(9):2468-70.
62. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respiratory Res. 2001 Jun;2(3):1-5.
63. CDC. Initial therapy for Tuberculousis in the era of MDR. Recommendations of the advisory council for the elimination of tuberculousis. MMWR Recomm. Rep. 1993;42(7):1-8.
64. Zimhony O, Vilcheze C, Jacobs WR Jr. Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene. J Bacteriol. 2004;186(13):4051-4055.
65. Scorpio A, Lindholm-Levy P, Heifets Let al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 1997 Mar 1;41(3):540-3.
66. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 1996 Jun;2(6):662-7.
67. Mdluli K, Slayden RA, Zhu Y, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Sci. 1998;280(5369):1607-1610.
68. Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Sci. 2011;333(6049):1630-1632.
69. Chang KC, Leung CC, Yew WW, et al. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2012;56(11):5465-5475.
70. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis. 2003;7(1):6-21.
71. Shah N, Wright A, Bai G, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380-387.
72. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Report no. WHO/HTM/TB/2010.3. 2010, Geneva: The Organization.
73. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33(4):871-881.
74. Calver AD, Falmer AA, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis. 2010;16(2):264-271.

75. Cox HS, Sibilia K, Feuerriegel S, et al. Emergence of extensively drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med. 2008;359(22):2398-2400.

76. Grange JM, Stanford JL. Dogma and innovation in the global control of tuberculosis: discussion paper. J R Soc Med. 1994;87(5):272-275.
77. Rook GA, Hernandez-Pando R. The Pathogenesis of Tuberculosis. Annual Rev Microbiol. 1996;50:259-284.
78. Sterling TR, Bethel J, Goldberg S, et al. The Scope andImpact of Treatment of Latent Tuberculosis Infection in the United States and Canada. Am J of Resp Critical Care Med. 2006;173(8):927-931.
79. Campbell IA, Bah-Sow O. Pulmonary tuberculosis: diagnosis and treatment. British Med J, 2006;332(7551):1194-1197.
80. World Health Organization, Stop TB Initiative (World Health Organization). Treatment of tuberculosis: guidelines. WHO;2010.
81. Ruiz-Manzano J, Blanquer R, Calpe JL, et al. Diagnosis and Treatment of Tuberculosis. Arch Bronconeumol. 2008;44(10):551-566.
82. Flynn JL, Chan J. Immunology of Tuberculousis. Annual Rev Immunol. 2001;19:93-129.
83. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol. 2006;208(2):261–269.